Medication adherence trends with statins

Advances in Therapy

Volumn 22, Issue 2, 2005, Pages 163-171

  Huser, Michelle A ^a   Evans, Tamara S ^b   Berger, Val ^c  

^a BUTLER UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c LCC   (United States)

Author keywords

Adherence; Atorvastatin; Dyslipidemia; Pharmacy; Pravastatin; Retrospective; Simvastatin; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 21044451014     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849887     Document Type: Article

References (19)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group (4S). Lancet. 1994;344:1383-1389.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
6. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
7. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
9. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
10. EUROASPIRE III and Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:995-1001.
11. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;228:2880-2883.
12. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868-2869.
13. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc. 2000;40:157-165.
14. Day D. Use of pharmacy claims databases to determine rates of medication adherence. Adv Ther. 2003;20:164-176.
15. The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997;18:1718-1724.
16. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 1997;241: 317-325.
17. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332: 1125-1131.
18. Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ. 1993;307:846-848.
19. Akishita M, Ouchi Y, Toba K, et al. Compliance with prescriptions and adverse drug reactions in the elderly [in Japanese]. Nippon Ronen Igakkai Zasshi. 1995;32:178-182.